ORAMED PHARMACEUTICALS INC. Debt Instrument, Fair Value Disclosure
ORAMED PHARMACEUTICALS INC. (ORMP) had Debt Instrument, Fair Value Disclosure of $4.64 million as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentFairValue · last filed 2026-03-26
- 2025-12-31: Debt Instrument, Fair Value Disclosure $4.64M.
| Period end | Debt Instrument, Fair Value Disclosure |
|---|---|
| 2025-12-31 | $4.64M 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |